3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Aditum Bio Fund 3Filed to raise in 2024, with no closing reported yet. | 2024 | $400M | $0 | 0 |
| Aditum Bio Fund 2Filed to raise in 2021, with no closing reported yet. | 2021 | $250M | $0 | 0 |
| Aditum Bio Fund 1 | July 2019 | $133M | $133M | 26 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
7 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Christian KleeNot on the current fund | Quiet | None listed | 1 |
Classified sectors of Aditum Bio’s own portfolio companies, based on 11 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Aditum Bio’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| ARCH Venture Partners | 4 | Beam Therapeutics, eGenesis, LYCERA, Petra Pharma |
| Kendall Capital Partners | 2 | eGenesis, LikeMinds, Inc./DE |
| Versant Venture Capital | 2 | Century Therapeutics, Graphite Bio |
| Absolute Return |
| 0 |
| Ilan ZipkinNot on the current fund | Quiet | None listed | 3 | 0 |
| Joseph Jimenez | Quiet | Biotech & pharma | 4 | 0 |
| Joshua GertsmanNot on the current fund | Quiet | None listed | 1 | 0 |
| Mark Fishman | Quiet | Biotech & pharma | 2 | 0 |
| Paul Sekhri | Quiet | Biotech & pharma, Digital health, Enterprise software | 11 | 0 |
| Praveena KandulaNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| vTv Therapeutics |
| Balcera Fund Ltd | 1 | vTv Therapeutics |
| Buckeye Fund Ltd | 1 | vTv Therapeutics |
| Cadence Alternative Investments | 1 | vTv Therapeutics |
| Cascade Fund Ltd | 1 | vTv Therapeutics |
| Cedar Investments Ltd | 1 | vTv Therapeutics |
| Charles2 Fund Ltd | 1 | vTv Therapeutics |
| Clear Box Investments Ltd | 1 | vTv Therapeutics |
| Corktown Fund Ltd | 1 | vTv Therapeutics |
| Diversified Absolute Return | 1 | vTv Therapeutics |
| GCM Better Futures | 1 | vTv Therapeutics |
| GCM Fat Hunter | 1 | vTv Therapeutics |
A shared board seat: a company where filings name a Aditum Bio partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
